A Clinical Evaluation of an Esterified Hyaluronic Acid Matrix in Burn Patients for STSG
A Clinical Evaluation of an Esterified Hyaluronic Acid Matrix on Preparing Wounds in Burn Patients for Split-thickness Skin Grafting
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Has a wound originating from a thermal or electrical burn
- Target burn area is less than 20% of TBSA
- Target burn wound is greater than 0.5% of TBSA
- Patient has undergone escharectomy procedure or will undergo escharectomy on the target burn and resulting wound will likely need a split thickness skin graft, but wound site is not immediately ready for grafting
- For patients with diabetes, an A1C hemoglobin level between 11 percent (taken within 90 days)
Exclusion Criteria:
- Current active diagnosis of substance abuse, per the Investigator
- Patient currently taking non-inhaled corticosteroids
- Patient needs or is likely to need negative pressure wound therapy of the target wound after application of Hyalomatrix Wound Device
- Patient is pregnant, planning to become pregnant during study period, or breastfeeding
- Unstable medical condition as determined by the site investigator
- Patients with known sensitivities to hyaluronan, hyaluronan derivatives, silicone, or any other ingredients of the Hyalomatrix Wound Device
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Esterified hyaluronic acid matrix
|
A non-woven pad composed of esterified hyaluronic acid, covered with a semipermeable silicone layer to protect the wound and control water vapor loss
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number of Days From Initial Application of Wound Matrix to Approval of Wound to Receive a Split Thickness Skin Graft
Time Frame: Baseline to 42 days
|
Baseline to 42 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Wound Volume From the Time Prior to Application of the Wound Device to the Time Before the Application of STSG and After STSG
Time Frame: Baseline to 42 days
|
Baseline to 42 days
|
|
|
Length of Stay in Inpatient Unit
Time Frame: Baseline to 42 days
|
Baseline to 42 days
|
|
|
Patient Pain Rating
Time Frame: Baseline to 42 days
|
Baseline to 42 days
|
|
|
Proportion of Split Thickness Skin Graft Take for the Wound at 28 Days
Time Frame: 28 days
|
28 days
|
|
|
Proportion of Patients Who Develop an Infection of the Target Wound at Any Time Per Confirmation With Culture
Time Frame: Baseline to 70 days
|
Baseline to 70 days
|
|
|
Subject Discharge Destination
Time Frame: Baseline to 70 days
|
The facility that the subject is discharged to will be captured.
|
Baseline to 70 days
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- MED-2018-DIV31-006
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.